Schreiber R, Lewis C, Crane K. Patient Assessment of Foam Attributes from the Tazarotene Foam, 0.1%, Phase III Trials and Potential Impact on Patient Compliance. J of Skin [Internet]. 2018Dec.17 [cited 2024Sep.20];2:S57. Available from: https://dermsquared.com/skin/article/view/455